Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector
Key findings
AAV2.5T is a chimeric serotype combining AAV2 and AAV5 capsid sequences. Enhanced muscle transduction efficiency with improved spread compared to AAV2 or AAV5 alone. Demonstrated therapeutic efficacy in DMD preclinical models.